Active Surveillance Appropriate for Favorable Intermediate-Risk PCa
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
Even men who test negative for mutations in the BRCA1/2 DNA repair genes may have increased risk for prostate cancer progression when they have certain family history.
Study findings support surveillance for urethral recurrence after radical cystectomy.
During the COVID-19 pandemic, neoadjuvant ADT has been used as a way to delay initiation of daily radiation therapy, but it may not be appropriate for all men.
Individuals diagnosed with a stress-related disorder may warrant increased surveillance of their kidney function, according to study investigators.
A past or present diagnosis of inflammatory bowel disease elevates the risk of progression to kidney failure among patients with IgA nephropathy, according to investigators.
Kidney graft survival at 15 years after transplantation did not differ between selected patients treated with and without maintenance corticosteroids, according to recent study findings.
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
The early morning fasting urine-to-plasma urea ratio reflects the kidneys’ urine-concentrating capacity, which may decline early in ADPKD, according to investigators.
In a study of patients on active surveillance, men with greater periprostatic fat had shorter prostate cancer progression-free survival.